Cue Biopharma vs Keros Therapeutics
CUE and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CUE and KROS compare
Keros Therapeutics is the larger company, worth 1.4 times as much as Cue Biopharma ($189M against $136M).
Cue Biopharma grew revenue faster over the last twelve months (354% versus −83.4% for Keros Therapeutics).
Keros Therapeutics keeps more of each dollar of sales as profit, with a net margin of −153% compared with −436% at Cue Biopharma.
Keros Therapeutics scores higher on the StockData Score (9 against 8 for Cue Biopharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CUE | KROS |
|---|---|---|
| Size and price | ||
| Market cap | $136M | $189M |
| Share price | $18.66 | $9.54 |
| Change, 1 year | −8.7% | −44.0% |
| Change, 5 years | −95.8% | −84.1% |
| Beta (5Y) | 2.37 | 1.10 |
| Employees | 29 | 78 |
| StockData Score | ||
| Total score | 8 | 9 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 2 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.6× (better) | 4.7× |
| P/B | 58.7× | 0.7× (better) |
| FCF yield | −37.0% | −25.5% (better) |
| Fair value | – | $24.96 |
| Margin of safety | – | 61.8% |
| Growth | ||
| Revenue growth (TTM) | 354% (better) | −83.4% |
| Revenue growth, 5Y average | 54.2% | – |
| Net income growth (TTM) | – | −196% |
| EPS growth (TTM) | – | −282% |
| Profitability | ||
| Operating margin | −262% | −181% (better) |
| Net margin | −436% | −153% (better) |
| FCF margin | −133% | −119% (better) |
| Return on equity | −1603% | −12.6% (better) |
| Return on invested capital | – | −389% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 1.25 | 18.14 (better) |
| Altman Z-score | −30.32 | 2.05 (better) |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 22.6% | 101% |
| Held by insiders | 17.4% | 53.3% |
| Insider net buying, 12 months | −$2.3M | −$447K (better) |
| Short interest, % of float | 14.4% | 11.7% |
Go deeper
- CUE stock overview
- CUE income statement
- CUE valuation and score
- KROS stock overview
- KROS income statement
- KROS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.